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A 3D bioprinter platform for 
mechanistic analysis of tumoroids 
and chimeric mammary organoids
John A. Reid1, Xavier-Lewis Palmer  1, Peter A. Mollica2,3, Nicole Northam4, Patrick C. Sachs2 
& Robert D. Bruno  2
The normal mammary microenvironment can suppress tumorigenesis and redirect cancer cells to 
adopt a normal mammary epithelial cell fate in vivo. Understanding of this phenomenon offers great 
promise for novel treatment and detection strategies in cancer, but current model systems make 
mechanistic insights into the process difficult. We have recently described a low-cost bioprinting 
platform designed to be accessible for basic cell biology laboratories. Here we report the use of this 
system for the study of tumorigenesis and microenvironmental redirection of breast cancer cells. We 
show our bioprinter significantly increases tumoroid formation in 3D collagen gels and allows for precise 
generation of tumoroid arrays. We also demonstrate that we can mimic published in vivo findings by 
co-printing cancer cells along with normal mammary epithelial cells to generate chimeric organoids. 
These chimeric organoids contain cancer cells that take part in normal luminal formation. Furthermore, 
we show for the first time that cancer cells within chimeric structures have a significant increase in 
5-hydroxymethylcytosine levels as compared to bioprinted tumoroids. These results demonstrate the 
capacity of our 3D bioprinting platform to study tumorigenesis and microenvironmental control of 
breast cancer and highlight a novel mechanistic insight into the process of microenvironmental control 
of cancer.
Understanding the capacity of the local microenvironment (niche) to control the fate of cells is of vital impor-
tance to developmental biology, cancer biology, and regenerative medicine1–4. To this end, our group and col-
leagues have previously demonstrated that the regenerating mouse mammary gland can direct stem cells of 
non-mammary origin to a mammary epithelial cell fate in vivo1,5–15. The capacity of the local microenvironment 
to control differentiation extends to cancer cells as well6,10,15,16. Specifically, the regenerating mouse mammary 
gland directs normal mammary epithelial differentiation of human NTERA-2 teratocarcinoma6, human breast 
cancer15, and mouse MMTV-Erb2 mammary cancer cells10. For these studies, normal mouse mammary epi-
thelial cells (MECs) were mixed with non-mammary or cancer cells and co-injected into the epithelial divested 
mammary fat-pads of recipient mice. The resulting glands contained chimeric epithelial trees consisting of both 
normal MECs and redirected non-mammary/cancer-derived cells. The redirected cells displayed normal MEC 
morphology and function and could self-renew and contribute to second generation outgrowths demonstrating 
they had not been terminally differentiated. These results were interpreted to mean that the non-mammary/can-
cer cells would be incorporated into niches as they were reformed by the dispersed MECs during transplantation. 
Once incorporated, they would adopt the function of that niche and therefore contribute to the regenerating 
gland by producing functional mammary epithelial progeny.
Mechanistic understanding of the capacity of the local microenvironment to direct the fate of cancer cells is 
important for cancer therapy and diagnostics. However, limitations of the in vivo model render such insights dif-
ficult to achieve. These limitations include low efficiency, low throughput, lack of an all human system, and limita-
tions in experimental manipulation and cellular control. A complementary in vitro model system that allowed for 
precise control and reproducibility would therefore be beneficial. However, standard in vitro cell culture systems 
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do not have the 3D architectures necessary to elicit the functional organization and cellular relationships of the 
in vivo environment17. For these reasons, 3D in vitro and ex vivo cell culture systems represent an indispensable 
tool to investigate the processes related to tissue and tumor formation. Unfortunately, current in vitro 3D models 
have many shortcomings, limiting their ability to investigate these processes18. For example, the overwhelming 
majority of these standard 3D systems rely on handheld-pipetting of premixed-ratios of cells with ECM substrates 
prior to gelling, or by manually blotting cell mixtures on top of a pre-formed ECM gel19,20. As a result, the distri-
bution, size, morphology, and cell types within the resulting organoids vary greatly, which leads to difficulty in 
interpreting and reproducing experimental results21.
We have recently described the adaptation of a low-cost accessible 3D bioprinter for the purpose of precise 
cell printing within 3D hydrogels22,23. This bioprinting platform was designed for use in basic cell biology lab-
oratories and can be used to generate large 3D mammary organoids in hydrogels23. Unlike traditional culture, 
the 3D bioprinted system precisely places cells allowing for greater control of organoid formation and experi-
mental consistency. Here we describe the adaptation of our mammary epithelial organoid printing protocol for 
the generation of 3D tumoroids and chimeric organoids. We demonstrate that both MCF-7 and MDA-MB-468 
human breast cancer cells incorporate into bioprinted organoids. We show that MCF-7 cells incorporated and 
contributed to luminal structure formation and undergo epigenetic alterations evidenced by significant increases 
in 5-hydroxymethylcytosine (5-hmC) levels. This system offers a significant improvement over traditional culture 
techniques and establishes a platform for future study into the microenvironmental control of cancer.
Results
Generation of patterned three-dimensional growth of mammary tumor cells. To determine 
the capacity of our bioprinting protocol to generate patterned 3D tumorigenic growths, we compared tumoroid 
formation efficiency in rat tail collagen gels between bioprinted and traditionally cultured green fluorescent pro-
tein (GFP) expressing MCF-7 and copGFP expressing MDA-MB-468 cells. MCF-7 and MDA-MB-468 represent 
luminal A and basal sub-types of breast cancer24. Our bioprinting method uses CNC processes to controllably-de-
posit cells in 3D locations of polymerized collagen I gels22. We bioprinted clusters of 40 tumor cells into equally 
spaced locations 300 µm apart (Fig. 1). The standard culturing protocol involves embedding dispersed cells into 
the hydrogel prior to polymerization. This method proved to be inefficient at generating tumoroid structures in 
collagen hydrogels. We quantitated the process by determining the frequency of wells that contained tumoroids 
(defined as cell clusters with volumes >0.001 mm3) between printed and traditionally cultured protocols. With 
traditional methods, MCF-7s and MDA-MB-468 cells never formed tumoroid structures (0/10 wells each, 2400 
cells/well). Conversely, bioprinting was significantly more efficient (p < 0.0001 by Fisher’s Exact Test), resulting 
in 100% efficiency (10/10 wells), with a printing efficiency of 95% (57/60 prints, 40 cells/print, 60 prints/well).
Our bioprinting assay identified a discrepancy between the growth morphologies of the two tumor cell lines 
throughout the 21-day culture period. MCF-7 tumor cells formed compact, sphere-like structures with little evi-
dence of coordinated growth among neighboring organoids, indicative of their previously known, non-invasive 
character (Fig. 1a,c,e)25. This allowed for patterned arrays of MCF-7 tumoroids to be printed (Fig. 1c). On the 
other hand, MDA-MB-468 cell growth illustrated the opposite effect, where invasive tumor cells equally dispersed 
into all radial directions of the rat tail collagen matrix, which resulted in a large, disordered structure lacking 
defined boundaries (Fig. 1b,d,f). These results are consistent with previous findings of enhanced invasive behavior 
of MDA-MB-468 cells25. Importantly, efficiency of tumoroid formation and organization was not impacted by 
modifications to print distances or cell number, so no additional optimization was undertaken. Our bioprinting 
device was designed to place minimal shear force on the cells and thus minimally impact their biology22. To 
confirm that the bioprinting process was not altering the phenotype of the cancer cells, we immunostained for 
cytokeratins 5 and 8 (CK5 and CK8). After bioprinting and tumoroid formation, MCF-7 cells remained CK8 
positive and CK5 negative (Fig. 2a) consistent with their luminal phenotype24; MDA-MB-468 cells remained dual 
positive for CK5 and CK8 consistent with previous reports24–26. Furthermore, after 21 days in culture, the two 
tumor lines had high percentages of ki67+ cells, a marker of proliferation (Fig. 2c,d). The percentage of ki67+ 
MCF-7 and MDA-MB-64 tumor cells was significantly greater than bioprinted non-tumorigenic MCF12a cells 
(P < 0.01; Fig. 2e). These results demonstrate the capacity of the bioprinter to efficiently and consistently generate 
tumoroid structures in hydrogels without disrupting the phenotype of the printed cells. This simple, accessible, 
and inexpensive system thus offers a superior methodology for standardization of tumoroid related assays over 
traditional culture methodologies.
Generation of chimeric structures in a 3D Gel. Given the need to develop 3D in vitro models to investi-
gate the molecular mechanisms underlying microenvironmental control of cancer cells, we began by determining 
the effectiveness of manual cell-matrix embedding to generate chimeric cell-organoids. Consistent with previous 
in vivo demonstrations, our in vitro chimera studies used a 5:1 ratio of normal to tumorigenic cells1. Thus, we 
mixed 5000 red fluorescent protein (RFP) labeled non-tumorigenic MCF-12A cells with 1000 cells from a single 
GFP tumorigenic cell line in neutralized rat-tail collagen and pipetted into wells of a 24 well plate and allowed the 
gel to polymerize. Under these conditions, MECs and tumorigenic cell lines were rarely able to generate chimeric 
organoid structures during the 21-day culture period (Fig. 3a). Analysis of the limited quantities of chimeric 
structures were further complicated by the excessive number and random distribution of MCF-12A organoids 
and persistence of unincorporated cancer cells within the hydrogel. This precluded any in-depth analysis of the 
redirected cells, as incorporation events were too sparse to facilitate any cellular or molecular analysis of redirec-
tion. However, random events did lead to occasional incorporation of cancer cells into chimeric structures (Supp. 
Fig. 1), which demonstrated the feasibility of a 3D in vitro model system.
To improve efficiency of chimeric structure formation, we next sought to guide the formation of chimeric 
organoids using our custom bioprinting system. We previously described our ability to standardize the frequency 
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of organoid formation through control of the initial cell quantities within bioprinted cell-deposits; cell-deposits 
containing at least 40 cells formed organoids within 7 days post-printing23. Therefore, we mixed MCF12A cells 
and tumorigenic MCF-7 or MDA-MB-468 cells in a 5:1 ratio as above, and then printed 66 nl of cell mixtures 
equivalent to 40 cells in equally-spaced linear (300 µm) and circular (500 µm) arrays inside collagen I gels. Unlike 
the random cell distribution of manual embedding, our bioprinting method maintained GFP-labeled tumorigenic 
cells within the immediate vicinity of RFP-labeled MCF12A cells post-printing (Fig. 3b). Chimeric structures 
formed rapidly, with large contiguous chimeric organoids obvious by day 7 (Fig. 3c). After 3 weeks in culture, the 
cell clusters formed into large, contiguous epithelial structures containing chimeric constituents from both cancer 
cell lines (Fig. 3d). Interestingly, time-lapse imaging indicated both MCF-7 and MDA-MB-468 tumorigenic cell 
lines interact with MCF-12A cells, and actively migrate inside MCF-12A organoids (Sup. Movies 1 and 2). This is 
consistent with the activity of non-tumorigenic MCF-12A cells in previous findings which move between print 
locations and continue to display movement within organoids23. Importantly, as these structures began to gen-
erate branched extensions, tumor cells remained equally dispersed within the networked structures (Fig. 3), and 
very rarely were cancer cells found in the hydrogel unincorporated into the chimeric organoid. We could print 
these chimeric structures in either linear or circular arrays, consistent with previous findings that showed both 
array configurations could yield large contiguous organoids23.
We next quantitatively compared manual embedding vs our 3D bioprinted method to determine the effi-
ciency of chimeric organoid formation. Surveys of manually-embedded gels indicated the initial 5000 MCF-12A 
cell-quantity resulted in a total of 929 ± 265 and 1060 ± 209 MCF-12A organoids at 7 and 14 days. Given the 5:1 
ratio of tumorigenic cells in the initial cell mixtures of chimeric experiments, we expected to observe tumori-
genic cells among 200 of the 1000 MCF-12A organoids in the embedded gels. Yet, among these organoids, only 
2.3 ± 0.5 and 5.5 ± 1.3 chimeric organoids were observed at 7 and 14 days, respectively. Thus, generating chimeric 
Figure 1. 3D Bioprinting of consistent MCF-7 and MDA-MB-468 tumoroids. (a1–3) MCF-7 cell deposits (40 
cells/deposit) spaced 300 µm apart at 1, 14, and 21 days post-printing. (b1–b3) MDA-MB-468 cell deposits 
(40 cells/deposit) spaced 300 µm apart at 1, 14, and 21 days post-printing. (c) Example of reliable printed 
array of GFP + MCF-7 tumoroids 21 days post-print with distinct structures. (d) Example of a linear array 
MDA-MB-468 tumor organoids at 21 days with all the multiple print sites fused into a single structure. (e,f) 
H&E stains of (e) MCF-7 and (f) MDA-MB-468 tumor organoids at 21 days. (Scale bars: a and b = 1 mm; c and 
d = 500 µm; e and f = 150 µm).
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organoids using manual embedding equaled a success rate of 1.15% and 2.75% at 7 and 14 days, respectively 
(Fig. 3a). Among experiments with 36 bioprinted cell-deposits, 34.7 ± 1.6 and 32.2 ± 3.8 chimeric cell-organoids 
formed at 7 and 14 days, respectively. Thus, bioprinted cell mixtures corresponded to a 96.4% and 89.5% chimeric 
organoid formation frequency at 7 and 14 days (Fig. 3a). When compared to manual methods, the number of bio-
printed chimeric organoids increased significantly after both 1 week (p < 0.001) and 2 weeks (p < 0.01). Overall, 
this data highlights the increased efficiency of our 3D bioprinter to generate chimeric organoid-structures com-
pared to manual matrix embedding procedures.
In addition to increased efficiency, our bioprinting device also provides the ability to generate unique com-
binations, geometric configurations, and temporal additions of multiple cell types. Previously, we described 
organoid fusion events where neighboring MECs initiate the formation of directional extensions to generate 
organized large epithelial structures23. Presumably, the areas where these restructuring processes occur contain 
‘normal’ developmental cues. To determine if human cancer cell organoids could be influenced by these inter-
actions, we used our bioprinting apparatus to place tumor-only cell-deposits between MCF12A cell-deposits in 
equally spaced (300 µM), linear arrays (Fig. 3e). MDA-MB-468 cells located in-between normal organoids were 
incorporated into large, chimeric organoid structures and failed to produce any tumoroid structures on their own 
(Fig. 3f). This demonstrates that mixed ‘ink’ is not required for chimeric structure formation, which adds to the 
versatility of the system.
Staining of 5 µm cross-sections of bioprinted chimeric organoids for GFP confirmed incorporation of the tum-
origenic cells into the MCF12a organoids (Fig. 4a,b). Notably, GFP+ MCF-7 cells were found to take part in lumi-
nal formation, appearing in linear groups of cells alongside GFP- MCF12A cells lining lumens (Fig. 4a), which 
was never observed when MCF-7 cells were bioprinted alone (Fig. 1). GFP+ MDA-MB-468s were also found 
integrated within a single 5 µm plane of MCF12A organoids (Fig. 4b). In general, MDA-MB-468 cells appeared 
as dispersed single cells rather than clusters, and we did not observe them lining lumens. Together, these results 
indicate our bioprinting process effectively generates chimeric structures, which holds the potential to mimic the 
incorporation of cancer cells within normal mammary structures previously described in vivo1,2,6–11,13–15.
Figure 2. Bioprinted tumoroids maintain expected cytokeratin expression and high percentage of proliferative 
cells. (a,b) MCF-7 tumoroids stained negative for CK-5 (green) and positive for CK-8 (red). B) MDA-MB-468 
tumoroids stained positive for both CK-5 (green) and CK-8 (red). (c,d) Ki67 staining of MCF-7 (c) and 
MDA-MB-468 (d) tumoroids. (e) Quantitation of ki67+ MCF-7 and MDA-MB-468 cells compared to MCF-
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Integration into chimeric organoids causes increase in 5-hmC levels in MCF-7 Cells. To validate 
our model system as a methodology for studying molecular basis of cancer cell redirection, we next sought to 
determine if cancer cells integrated into 3D organanoids underwent epigenetic alterations mediated by their 
microenvironment. As the cancer cells retain genetic abnormalities in the chimeric structures in vivo6, changes 
in function are likely epigenetically mediated. It has been shown that cancer cells have reduced levels of 5-hmC27. 
5-hmC is an intermediary in active demethylation process and can be detected in situ. We therefore explored 
whether incorporation in chimeric structures in vitro would alter 5-hmC levels in cancer cells. 21 days post-print, 
we confirmed bioprinted MCF-7 cells had significantly less 5-hmC than non-tumorigenic MCF-12A by immuno-
fluorescence (Fig. 5). When incorporated into chimeric organoids however, MCF-7 cells had a significant increase 
in 5-hmC levels, up to that seen in non-tumorigenic MCF12A cells (Fig. 5b,c). This supports a model where 
incorporation into a normal mammary microenvironment mediates epigenetic alterations in the cancer cells, 
allowing for them to take part in normal morphological structures. In this way, this work perfectly mimics our 
results in vivo, and underscores the utility of our system for studying microenvironmental control of cancer cells.
Figure 3. Generation of chimeric organoids using a 3D bioprinter. (a) Chimeric organoid formation was 
significantly improved by use of the 3D bioprinter compared to standard culture methods. ***p < 0.001. (b–d) 
Example of a typical large chimeric organoid generated by a 500 µm spaced print of a circle print pattern of a 5:1 
ratio of MCF-12A (red) and MDA-MB-468 (green) cells at day 3 (b), day 7 (c) and day 21 (d). (e,f) Example of 
300 µm spaced alternating prints of tumorigenic MDA-MB-468 cells (green) and MCF-12A cells (red) at day 1 
(e) and day 7 (f) demonstrating incorporation of cancer cells into the organoid. (Scale bars: b–d = 500 µm; e and 
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Discussion
This work provides a description of how our bioprinting technology can be used to standardize current and future 
chimeric models of 3D epithelial cell culture assays. We demonstrate the superiority of our bioprinting system 
over conventional manual embedding methods for studying tumor cell behaviors, particularly in the context 
of cancer cell redirection. Our low cost, open source, and accessible system is superior to traditional culture 
methods in generating controllable, precise tumoroid arrays for assay standardization. While many bioprinting 
apparatuses have been described that offer more robust and complex printing dynamics28, these systems are 
often beyond the reach of traditional cancer laboratories. Our simplistic design of an open source system that 
can be downloaded (www.odustemcell.org), printed and used in any laboratory improves upon the widely used 
traditional 3D culture assays to increase efficiency and reproducibility and allow for standardization of assays 
across laboratories. In addition, this system can be adapted for various drug screening and clonogenic stem cell 
associated assays.
Our laboratory has interest in the role of the microenvironment in controlling cancer cell behavior. The model 
system described here is the first system to allow robust analysis of this process in vitro. We believe the major 
advantage of our system in this context is the ability to print localized concentrations of mixed cell populations 
at equal distances. In random culture techniques, chimeric formation is likely limited by cellular concentration. 
Too many cells limits the formation of 3D structures, while too few cells limits the probability of chimeric struc-
tures forming. However, by condensing cells within a small 3D location (<100 nl of extruded fluid), we can get 
efficient chimeric structure formation. In these chimeric structures the cancer derived cells took part in normal 
organoid formation, consistent with previous in vivo results. While we did not specifically quantitate the process, 
we noted that the ratio of cancer to normal cells decreased in the fully formed structures. This is consistent with 
the interpretation that the normal microenvironment suppresses the growth of the cancer cells. This platform also 
allows for future studies into the temporal and spatial constrictions of cancer cell redirection. As demonstrated 
in Fig. 3e,f, cancer cells can be printed near normal cells in separate injections. This will allow for analysis of the 
effect of placing tumor cells around or near pre-formed organoids to help decipher differential effects of signaling 
during organoid development versus maintenance. The efficiency of cancer cell integration in the chimeric studies 
also allows for ease in isolation, without concern for contamination from unincorporated cancer cells. This will 
allow for fluorescent activated cell sorting of chimeras. Furthermore, because of the capacity of the printer to 
efficiently generate chimeric structures, future studies will explore the transplantability of 3D bioprinted chimeric 
organoids into cleared mammary fat pads. This would greatly increase the efficiency of the in vivo model.
Figure 4. Incorporation of MCF-7 and MDA-MB-468 cells into chimeric organoids. (a,b) Immunofluorescence 
staining of 5 µm cross-sections of bioprinted chimeras with anti-GFP antibodies (green) reveals incorporation 
of MCF-7 (a) and MDA-MB-468 (b) cells. MCF-7 cells appeared in clusters contributing to luminal formation 
while MDA-MB-468 cells remained as single cells and were not observed lining the luminal layer. Sections are 
counterstained with DAPI (blue). All samples were analyzed 21 days post-print. Scale bars = 50 µm.
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In addition, this report is the first to demonstrate a change in 5-hmC levels in cancer cells upon redirection 
by a normal microenvironment. This finding is particularly interesting given recent results that linked EGFR 
mediated MAPK signaling to decreases in 5-hmC levels in cancer cells29. It was also previously shown that Erb2 
phosphorylation in MMTV-Erb2 mouse mammary tumor cells was suppressed during chimeric gland formation 
in vivo or during co-culture in vitro10. Future studies using the 3D bioprinted approach outlined here can investi-
gate this potentially important mechanistic insight.
We recently describe the capacity of normal murine mammary ECM to direct differentiation of testicular 
and embryonic stem cells inside the mouse mammary gland30. The 3D bioprinting technology outlined here can 
also facilitate well controlled future studies aimed at exploring the role of the normal ECM in directing cell fate. 
This has the potential to develop not only mechanistic insights into the role of the ECM in controlling cell fate, 
but also for the development of all-human biomimetic culture systems. Future studies will also take advantage of 
the system to manipulate additional parameters such as localized gel stiffness to explore the role of mechanical 
contributions to cancer cell redirection.
Understanding the bidirectional communication between tumor cells and their microenvironment represents 
a powerful, advantageous way to investigate the mechanisms that influence disease promotion and progression. 
Furthermore, identifying the contextual contributions related to normalizing or reversing the tumor-specific 
ECM associated with cancer stands as an interesting target for novel screening methods and therapeutic targets 
for clinical tumor therapy. The system described here offers a novel, high-throughput, and reproducible experi-
mental strategy to study this phenomenon. Furthermore, this study provides a foundation for the observations 
made in the mammary gland to be tested in other cellular systems. This is facilitated by the open source nature 
of our printing protocols, which can easily be adapted to any 3D culture system. This offers our laboratory and 
others interested in this field the ability to develop experiments built off the printing protocols outlined here.
The capacity of normal cells to produce microenvironments (niches) capable of controlling the fate of cancer 
cells offers a unique insight into the biology of cancer. To study this, more robust model systems are required. 
The process described here, the adaptation of a low-cost and accessible bioprinting system for the generation of 
normal/tumor chimeras, achieves this goal. Our system efficiently generates normal human mammary organoids 
with cancer cells incorporated throughout, mimicking published in vivo findings in mice. This process was used 
to identify changes in 5-hmC levels within cancer cells incorporated into chimeras, consistent with a model where 
the normal microenvironment mediates epigenetic changes to redirect the cancer cells away from a tumorigenic 
fate. Thus, our bioprinting platform allows for mechanistic insight into the process of cancer cell redirection, and 
serves as an important platform for future studies into the process.
Methods
Cell culture. The immortalized non-tumorigenic human breast epithelial cell line, MCF-12A, and the breast 
carcinoma cell lines MCF-7 and MDA-MB-468 were purchased from American Type Culture Collection (ATCC). 
MCF-12A cells are considered a model for normal human MECs. The MCF-7 cell line represents a rapidly grow-
ing, luminal carcinoma cell line that is estrogen receptor-positive and non-invasive24,31. MDA-MB-468 cells are a 
basal, EGF receptor rich, estrogen receptor-negative and invasive breast cancer cell line24,25,32. All cells were stably 
transduced with premade lentiviral vectors to express the following: MCF-12A cells expressed RFP form the 
CMV enhancer/chicken β-actin promoter (CAG; Cellomics Technology, MD, USA); MCF-7 cells expressed GFP 
from the eIF promoter (Cellomics Technology) and MDA-MB-468 cells expressed copGFP (TurboGFP) from the 
eIF promoter (Systems Biosciences).
All cells were maintained on 2D tissue culture plastic prior to printing. MCF-12A cells grown in DMEM/
F12, 5% Horse Serum, 20 ng ml−1 hEGF, 0.01 mg ml−1 bovine insulin, 500 ng ml−1 hydrocortisone and 1% ABAM 
Figure 5. Incorporation into chimeric organoids significantly increases 5-hmC levels in MCF-7 cells.  
(a) Representative image of bioprinted MCF-7 cells (green) containing low levels of 5-hmC 21-days post-print. 
(b) Representative image of a chimeric organoid 21-days post-print containing MCF—7 (green) cells containing 
increased levels of 5-hmC (red) than when printed alone. Inset images in merged panel show higher magnification 
of the region of interest demonstrating absence or presence of 5-hmC in the nucleus. (c) Graph of the mean 
fluorescent intensity of 3 independent samples measured across 9 sections demonstrating incorporation of MCF-7 
cells into chimeric organoids significantly increases (***p < 0.001) their 5-hmC levels, normalizing them to that 
seen in MCF12A cells. Scale bars = 50 µm.
Total 5-hmC Levels 
_ MCF-7(GFP) _ Merge 
_ MCF-7(GFP) _ Merge 
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(all purchased from ThermoFisher). MCF-7 and MDA-MB-468 cells were maintained in Dulbecco’s Modified 
Eagle’s Medium supplemented with 10% fetal bovine serum (FBS, Life Technologies) and 1% Antibiotic/
Antimycotic(ThermoFisher). All cells were cultured at 37.0 °C and 5.0% CO2. After 80% confluence, the cells were 
dissociated using TrypleE (ThermoFisher) and collected by centrifugation. Chimeric organoids were cultured 
using DMEM/F12, 5% Horse Serum, 20 ng ml−1 hEGF, 0.01 mg ml−1 bovine insulin, 500 ng ml−1 hydrocortisone 
and 1% Antibiotic/Antimycotic (ThermoFisher).
Preparation of 3D collagen ECMs. For both cell-matrix manual embedding and 3D bioprinting experi-
ments, 3D rat-tail collagen gels were made according to manufacture protocols. Briefly, with all materials on ice, 
rat-tail collagen (Corning) was diluted to a final concentration of 1.3 mg/ml with the addition of 1X PBS, and 
1 N NaOH to a neutral pH. To polymerize gels, the 4 °C neutralized rat-tail collagen was then dispensed into 
multi-well plates and then incubated at 37 C for 60 minutes.
Manual Cell-matrix embedding. For epithelial cell only manual cell-matrix embedding studies, single cell 
suspensions of cells were mixed with 4 °C 1.3 mg/ml final concentration neutralized rat tail collagen I (Corning) 
as described previously23. Mixtures were then pipetted into a 24 well plate and allowed to solidify for 1 hour in 
a laboratory incubator at 37.0 °C. After gelation (solidification), 500 µl of cell appropriate cell media was added 
to the wells. For chimeric studies, MCF-12A cells were mixed with one of the two tumorigenic cell lines at a 5:1 
ratio. Immediately after mixing with neutralized rat-tail collagen, 500 µl gel material containing 2400 (cancer 
cells alone) or 6000 (chimeric studies) cells was dispensed into a 24 well plate and allowed to solidify as described 
above.
3D bioprinting. The 3D bioprinter used in these studies is a fully customized Felix 3.0 described previously22. 
Our 3D bioprinter is used to robotically dispense various cells into specified 3D locations of a polymerized col-
lagen gel22,23. The 3D files to manufacture our bioprinter are freely available from our website (www.odustemcell.
org). It uses a microstepper motor joined to a fine-resolution leadscrew which controls a plunger inserted into 
the rear opening of a glass pulled micropipette (Drummond Science Company). All glass pulled pipettes were 
manufactured on a Sutter P97 programmable pipette puller and are standardized to a tip diameter of 50 μm. 
Printing operations were all performed as previously described22,23. Briefly, neutralized collagen I gel material 
was dispensed into a 24 well plate as described above. To manufacture the ‘bio-Ink’, MCF-12A, MCF-7 and 
MDA-MB-468 cells were dissociated into single cells using TrypleE (ThermoFisher), centrifuged at 300 × g, and 
re-suspended in media to a concentration of 60 × 104 cells ml−1. For chimeric experiments, cells were then mixed 
to a 5:1 ratio and loaded into the injection device affixed to the printer. Printing operations were optimized to 
extrude specified numbers of cells (40 cells/injection event) inside the collagen I gel via a CNC insertion routine 
which deposited cell containing media (total of 66 nl/injection event) at a specified ‘target’ location inside the 
24-well dish containing the already polymerized collagen I gel. Users specified parameters are set via a custom 
MATLAB program, which sets the number of intended wells, printing locations, distances among printing loca-
tions, and the number of cells per target location. The subsequently outputted G-code CNC routine is then loaded 
into a free-ware printer control software (Repetier Host), and the routine is then initiated in the printer follow-
ing the loading of the ‘bio-ink’ into the injection device. The bioprinting system was located inside a benchtop 
biosafety cabinet during all printing operations. The heated print bed was set to 37 °C for all printing operations.
Histology and immunofluorescence Staining. Unless otherwise noted, samples were fixed in 10% NBF 
21-days post-printing. Paraffin embedded sections were processed using standard immunohistochemistry pro-
tocols. All sections underwent heat-mediated antigen retrieval using pH 9 Tris-EDTA with 0.05% tween 20 prior 
to staining. Primary antibody incubations were performed in a humidified chamber at 4 °C overnight (16 hrs). 
Secondary antibody incubations were performed at room temperature for 1 hr. All sections were counterstained 
with DAPI and imaged using a Zeiss Axio-observer Z1 fluorescent microscope. Image processing was completed 
with Zeiss Zen software.
The following primary antibodies were used: anti-green fluorescent protein rabbit IgG Alexafluor 488 con-
jugated (1:75; Invitrogen A21311); chicken anti-GFP (1:1000; Abcam ab13970), rabbit anti-Turbo GFP (1:1000; 
ThermoFisher PA5-22688); rabbit monoclonal antibody to cytokeratin 5 [EP1601Y] (1:75; ab52635, Abcam), 
mouse monoclonal antibody to cytokeratin 8 [C-51] (1:35; ab2531, Abcam), rabbit monoclonal anti-5-hmC 
[RM236] (1:50; ThermoFisher MA5-24695). Appropriate Alexafluor 488 or 568 conjugated secondary antibodies 
(1:1000; ThermoFisher) were used for visualization.
For 5-hmC quantitation, fluorescent intensity was quantified within cell nuclei using Zeiss Zen software. 
5-hmC levels were measured in MCF-7 cells grown alone as tumoroids, MCF12A cells growing as organoids, and 
MCF-7 cells growing within normal organoids with MCF12A cells (chimeras). In chimeras, MCF-7 cells were 
identified by co-staining with an anti-GFP antibody. Cells were measured from multiple sections across 3 inde-
pendent experiments. Individual cell measurements were then averaged for statistical analysis.
Statistical analysis. Values represent mean ± standard deviation of samples. Data represent three or more 
independent experiments. Tumoroid formation rates were compared using a Fisher’s exact test. Fluorescent inten-
sity of 5-hmC and percentage of ki67+ cells were compared by a one-way ANOVA with a Dunnett’s post-hoc. 
Efficiencies of chimeric gland formation were compared by a two-way ANOVA.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
authors on reasonable request.
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